OBJECTIVE: The Molecular Genetics of Schizophrenia (MGS2) project recruited an adult control sample of non-Hispanic European-ancestry (N=3,364) and African American (N=1,301) subjects. METHOD: Subjects gave consent to deposit phenotypic data and blood samples into a repository for general research use, with full anonymization of the sample. The authors compared the control sample with population census data for demographic data and with previous population surveys for anthropometrics and prevalences of psychiatric disorders as estimated by an Internet-administered questionnaire. RESULTS: The full MGS2 control sample includes 4,665 subjects (European-ancestry: N=3,364; African American: N=1,301), of whom 3,626 were included in the MGS2 genome-wide association study (GWAS). The sample is generally demographically representative of the U.S. population, except for being older and more female, educated, and affluent, although all strata are represented. Self-reported ancestry was consistent with genotypic and census data. Lifetime prevalences for depressive, anxiety, and substance use diagnoses were higher than in previous population-based surveys, probably due to use of an abbreviated self-report instrument. However, patterns such as sex ratios, comorbidity, and demographic associations were consistent with previous reports. DNA quality for the Internet collected/evaluated control sample was comparable to that of the face-to-face case sample. CONCLUSIONS: The Internet-based methods facilitated the rapid collection of large and anonymized non-Hispanic European-ancestry and African American control samples that have been validated as being generally representative for many aspects of demography, ancestry, and morbidity. Utilization of clinical screening data shared with the scientific community may permit investigators to select appropriate controls for some studies.
OBJECTIVE: The Molecular Genetics of Schizophrenia (MGS2) project recruited an adult control sample of non-Hispanic European-ancestry (N=3,364) and African American (N=1,301) subjects. METHOD: Subjects gave consent to deposit phenotypic data and blood samples into a repository for general research use, with full anonymization of the sample. The authors compared the control sample with population census data for demographic data and with previous population surveys for anthropometrics and prevalences of psychiatric disorders as estimated by an Internet-administered questionnaire. RESULTS: The full MGS2 control sample includes 4,665 subjects (European-ancestry: N=3,364; African American: N=1,301), of whom 3,626 were included in the MGS2 genome-wide association study (GWAS). The sample is generally demographically representative of the U.S. population, except for being older and more female, educated, and affluent, although all strata are represented. Self-reported ancestry was consistent with genotypic and census data. Lifetime prevalences for depressive, anxiety, and substance use diagnoses were higher than in previous population-based surveys, probably due to use of an abbreviated self-report instrument. However, patterns such as sex ratios, comorbidity, and demographic associations were consistent with previous reports. DNA quality for the Internet collected/evaluated control sample was comparable to that of the face-to-face case sample. CONCLUSIONS: The Internet-based methods facilitated the rapid collection of large and anonymized non-Hispanic European-ancestry and African American control samples that have been validated as being generally representative for many aspects of demography, ancestry, and morbidity. Utilization of clinical screening data shared with the scientific community may permit investigators to select appropriate controls for some studies.
Authors: Jessica Clark Newman; Don C Des Jarlais; Charles F Turner; Jay Gribble; Phillip Cooley; Denise Paone Journal: Am J Public Health Date: 2002-02 Impact factor: 9.308
Authors: Ronald C Kessler; Patricia Berglund; Wai Tat Chiu; Olga Demler; Steven Heeringa; Eva Hiripi; Robert Jin; Beth-Ellen Pennell; Ellen E Walters; Alan Zaslavsky; Hui Zheng Journal: Int J Methods Psychiatr Res Date: 2004 Impact factor: 4.035
Authors: Michael W Smith; Nick Patterson; James A Lautenberger; Ann L Truelove; Gavin J McDonald; Alicja Waliszewska; Bailey D Kessing; Michael J Malasky; Charles Scafe; Ernest Le; Philip L De Jager; Andre A Mignault; Zeng Yi; Guy De The; Myron Essex; Jean-Louis Sankale; Jason H Moore; Kwabena Poku; John P Phair; James J Goedert; David Vlahov; Scott M Williams; Sarah A Tishkoff; Cheryl A Winkler; Francisco M De La Vega; Trevor Woodage; John J Sninsky; David A Hafler; David Altshuler; Dennis A Gilbert; Stephen J O'Brien; David Reich Journal: Am J Hum Genet Date: 2004-04-14 Impact factor: 11.025
Authors: T Aalto-Setälä; L Haarasilta; M Marttunen; A Tuulio-Henriksson; K Poikolainen; H Aro; J Lönnqvist Journal: Psychol Med Date: 2002-10 Impact factor: 7.723
Authors: Maria Orlando; M Audrey Burnam; Robin Beckman; Sally C Morton; Andrew S London; Eric G Bing; John A Fleishman Journal: Int J Methods Psychiatr Res Date: 2002 Impact factor: 4.035
Authors: Bridget F Grant; Frederick S Stinson; Deborah A Dawson; S Patricia Chou; Mary C Dufour; Wilson Compton; Roger P Pickering; Kenneth Kaplan Journal: Arch Gen Psychiatry Date: 2004-08
Authors: Jubao Duan; Alan R Sanders; Winton Moy; Eugene I Drigalenko; Eric C Brown; Jessica Freda; Catherine Leites; Harald H H Göring; Pablo V Gejman Journal: Hum Mol Genet Date: 2015-05-28 Impact factor: 6.150
Authors: John M Hettema; Bradley T Webb; An-Yuan Guo; Zhongming Zhao; Brion S Maher; Xiangning Chen; Seon-Sook An; Cuie Sun; Steven H Aggen; Kenneth S Kendler; Po-Hsiu Kuo; Takeshi Otowa; Jonathan Flint; Edwin J van den Oord Journal: Biol Psychiatry Date: 2011-08-25 Impact factor: 13.382
Authors: Kaya K Jacobsen; Caroline M Nievergelt; Tetyana Zayats; Tiffany A Greenwood; Verneri Anttila; Hagop S Akiskal; Jan Haavik; Ole Bernt Fasmer; John R Kelsoe; Stefan Johansson; Ketil J Oedegaard Journal: J Affect Disord Date: 2014-10-12 Impact factor: 4.839
Authors: Alan R Sanders; Harald H H Göring; Jubao Duan; Eugene I Drigalenko; Winton Moy; Jessica Freda; Deli He; Jianxin Shi; Pablo V Gejman Journal: Hum Mol Genet Date: 2013-07-30 Impact factor: 6.150
Authors: Crystelle A Egan; Susan E Marakovitz; Julia A O'Rourke; Lisa Osiecki; Cornelia Illmann; Lauren Barton; Elizabeth McLaughlin; Rachel Proujansky; Justin Royal; Heather Cowley; Martha Rangel-Lugo; David L Pauls; Jeremiah M Scharf; Carol A Mathews Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2012-10-22 Impact factor: 3.568
Authors: Xianglong Zhang; Abdel Abdellaoui; James Rucker; Simone de Jong; James B Potash; Myrna M Weissman; Jianxin Shi; James A Knowles; Carlos Pato; Michele Pato; Janet Sobell; Johannes H Smit; Jouke-Jan Hottenga; Eco J C de Geus; Cathryn M Lewis; Henriette N Buttenschøn; Nick Craddock; Ian Jones; Lisa Jones; Peter McGuffin; Ole Mors; Michael J Owen; Martin Preisig; Marcella Rietschel; John P Rice; Margarita Rivera; Rudolf Uher; Pablo V Gejman; Alan R Sanders; Dorret Boomsma; Brenda W J H Penninx; Gerome Breen; Douglas F Levinson Journal: Biol Psychiatry Date: 2019-03-13 Impact factor: 13.382
Authors: Kenneth S Kendler; Gursharan Kalsi; Peter A Holmans; Alan R Sanders; Steven H Aggen; Danielle M Dick; Fazil Aliev; Jianxin Shi; Douglas F Levinson; Pablo V Gejman Journal: Alcohol Clin Exp Res Date: 2011-02-11 Impact factor: 3.455